Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
risedronate · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | treatment duration: 1 year |
| 2 | PLACEBO_COMPARATOR | treatment duration: 1 year |
| 3 | EXPERIMENTAL | duration treatment: 3 years |
| 4 | PLACEBO_COMPARATOR | treatment duration: 3 years |
| Name | Type | Description |
|---|---|---|
| risedronate | DRUG | During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child. |
| placebo | DRUG | placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child. |
Inclusion Criteria: * Study I: patients with FD, with bone pain intensity above 3 on visual analogical scale from 0 to 10 * Study II: patients with FD with at least one osteolytic lesion and no current bone pain Exclusion Criteria: * patients \< 8 years old * other diseases affecting bone metabol...
Risedronate is an investigational small molecule being studied for the treatment of fibrous dysplasia of bone, a musculoskeletal condition. It is currently in Phase 2 clinical development and has not been approved for this use. The drug is being evaluated for its effect on bone morbidity in patients with this condition.
Risedronate is a small molecule in the bisphosphonate class, which works by inhibiting bone resorption. It is being studied for its ability to reduce bone morbidity in patients with fibrous dysplasia of bone. The drug's mechanism involves targeting osteoclast activity to help manage the abnormal bone turnover associated with the disease.
Risedronate is being developed by Pulmonx Corporation, a company traded on the NASDAQ under the ticker symbol LUNG. The company is conducting clinical research to evaluate the drug's safety and efficacy for the treatment of fibrous dysplasia of bone.
Risedronate is in Phase 2 clinical development for the treatment of fibrous dysplasia of bone. It is an investigational drug and has not been approved by regulatory authorities. The Phase 2 trial has been completed, and the drug remains in the clinical development pipeline.
Risedronate has been studied in one completed Phase 2 clinical trial with the identifier NCT00445575. The trial, titled 'Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone,' enrolled 80 participants and was conducted in Belgium, France, Germany, and the Netherlands. The study was randomized, double-blind, and placebo-controlled.
Risedronate is a bisphosphonate, a class of drugs used to treat bone conditions. It is being studied specifically for fibrous dysplasia of bone. While it shares a mechanism with other bisphosphonates, risedronate is a distinct chemical entity being developed for this indication.